AGTC 501

Drug Profile

AGTC 501

Alternative Names: AGTC-501; rAAV2tYF-GRK1-RPGR

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Retinitis pigmentosa

Most Recent Events

  • 01 Jan 2018 Phase-I/II clinical trials in Retinitis pigmentosa (In children, In adolescents, In adults, In the elderly) in USA (Intraocular) (NCT03316560)
  • 13 Sep 2017 AGTC plans a phase I/II trial for Retinitis pigmentosa (X-linked; In children, In adolescents, In adults, In the elderly) in USA in January 2018 (NCT03316560)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top